Yinglan Tan of Insignia Ventures Partners says that beyond Singapore and Indonesia, Vietnam and Malaysia are emerging as key ...

London-based space biotech startup, Mass Balance, launched its first mission into space on Tuesday on a SpaceX Falcon 9 ...

The Boston-based drugmaker has been on a mission to build out the next generation of drug products beyond its cystic fibrosis ...

Vertex Pharmaceuticals is buying an endocrine treatment specialist for $10 billion.

The tuition-free program trained unemployed and under-employed Maryland residents for careers in biotechnology and biomedical ...

In South San Francisco, Genentech showed that recombinant DNA technology could transform medicine and create therapies once ...

Vertex will acquire Crinetics Pharmaceuticals for $10 billion, its largest deal yet, adding an approved rare-disease drug to ...

David Craig’s operating manual for building biotech companies in today’s market is now available in hardcover and as an ...

Wall Street sees bigger upside in VKTX, with Koyfin’s average target implying 120% upside versus 99% for BCRX.

VERAXA Biotech (NASDAQ: VRXA) announced the initiation of cell line development for its lead BiTAC(R) T-cell engager ...

Biotech companies are spending billions to perfect chemical formulas, only to be tripped up by the one variable they forgot ...